Layer-by-layer coated lipid–polymer hybrid nanoparticles designed for use in anticancer drug delivery
•Layer-by-layer technique was successfully implemented to formulate core–shell nanoparticles.•Chitosan and hyaluronic acid were employed to modify the surface of hybrid solid lipid nanoparticles.•The engineered nanoparticles enhance the circulation half-life and decrease the elimination of the loade...
Saved in:
Published in | Carbohydrate polymers Vol. 102; pp. 653 - 661 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Kidlington
Elsevier Ltd
15.02.2014
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | •Layer-by-layer technique was successfully implemented to formulate core–shell nanoparticles.•Chitosan and hyaluronic acid were employed to modify the surface of hybrid solid lipid nanoparticles.•The engineered nanoparticles enhance the circulation half-life and decrease the elimination of the loaded drug.•These structures have the potential to act as a vehicle to deliver medication to targeted tumor regions.
Polyelectrolyte multilayers created via sequential adsorption of complimentary materials may be useful in the delivery of small molecules such as anti-cancer drugs. In this study, layer-by-layer (LbL) nanoarchitectures were prepared by step-wise deposition of naturally derived chitosan and hyaluronic acid on negatively charged hybrid solid lipid nanoparticles (SLNs). A doxorubicin/dextran sulfate complex was incorporated into the SLNs. This resulted in the production of spherical nanoparticles ∼265nm in diameter, with a zeta potential of approximately −12mV. The nanoparticles were physically stable and exhibited controlled doxorubicin (DOX) release kinetics. Further pharmacokinetic manipulations revealed that in comparison with both free DOX and uncoated DOX-loaded SLNs, LbL-functionalized SLNs remarkably enhanced the circulation half-life and decreased the elimination rate of the drug. Cumulatively, our results suggest that this novel LbL-coated system, with a pH-responsive shell and molecularly targeted entities, has the potential to act as a vehicle to deliver medication to targeted tumor regions. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
ISSN: | 0144-8617 1879-1344 |
DOI: | 10.1016/j.carbpol.2013.11.009 |